...
首页> 外文期刊>Journal of the Chemical Society, Perkin Transactions 1 >Consecutive Pschorr-Sandmeyer reactions in a pyrazole series. Part 2. Access to the [2]benzopyrano[4,3-c]pyrazole system of pharmaceutical interest
【24h】

Consecutive Pschorr-Sandmeyer reactions in a pyrazole series. Part 2. Access to the [2]benzopyrano[4,3-c]pyrazole system of pharmaceutical interest

机译:吡唑系列的连续Pschorr-Sandmeyer反应。第2部分。获得具有药用价值的[2]苯并吡喃并[4,3-c]吡唑系统

获取原文
获取原文并翻译 | 示例
           

摘要

The diazonium salts obtained from 2-amino-N-methyl-N-(1-phenyl-3-methylpyrazol-5-yl)benzamide were reacted with cuprous oxide or copper at 5 or 25 degrees C under different pH conditions. Cuprous oxide at 25 degrees C and pH 6.25 yielded the racemic epimers (3'SR,4'RS)-and (3'SR,4'SR)-4'-hydroxy-2',4'-dihydro-2,5 dimethyl-2'-phenylspiro[isoindoline-1,3'-3'H-pyrazol]-3-ones 2 and 10 respectively, (RS)-2',4'-dihydro-2,5'-dimethyl-2'-phenylspiro[isoindoline 9 and N-methylphthalimide 8, The thermal transformation of 2 and 10 into the potentially pharmacologically active 3-methyl-1-phenyl[2]benzopyrano[4,3-c]pyrazol-5(1H) 4 was strongly dependent on the structure of the two epimers, When I was reacted with cuprous oxide or copper sulfate and sodium halide (chloride or bromide), in the presence of ascorbic acid as initiator, a mixture of epimers (3'SR,4'RS)- and (3'SR,4'SR)-4'-chloro(or bromo)-2',4'-dihydro-2,5'-dimethyl-2'-phenylspiro[isoindoline-1,3'-3' H-pyrazol]-3-ones 6b and 7b (or 6c and 7c) was obtained. The same epimers were obtained when the diazonium halides (chloride and bromide) 1b,c obtained from 2-amino-N-methyl-N-(1-phenyl-3-methyl-1H-pyrazol-5-yl)benzamide were treated with the appropriate classical Sandmeyer catalysts. The formation of the spiro compounds is based on consecutive Pschorr and Sandmeyer reactions. The X-ray crystal structures of the epimers 2 and 10 have been determined, confirming the given formulations. [References: 21]
机译:由2-氨基-N-甲基-N-(1-苯基-3-甲基吡唑-5-基)苯甲酰胺获得的重氮盐在5或25℃下在不同pH条件下与氧化亚铜或铜反应。在25摄氏度和pH 6.25下的氧化亚铜产生外消旋差向异构体(3'SR,4'RS)-和(3'SR,4'SR)-4'-羟基-2',4'-二氢-2,5二甲基-2'-苯基螺[异吲哚啉-1,3'-3'H-吡唑] -3-1和2,(RS)-2',4'-二氢-2,5'-二甲基-2' -苯基螺[异吲哚啉9和N-甲基邻苯二甲酰亚胺8,强烈地将2和10转变为具有潜在药理活性的3-甲基-1-苯基[2]苯并吡喃并[4,3-c]吡唑-5(1H)4。取决于两种差向异构体的结构,当我与抗氧化亚铜或硫酸铜和卤化钠(氯化物或溴化物)反应时,在抗坏血酸作为引发剂的情况下,差向异构体(3'SR,4'RS)的混合物-和(3'SR,4'SR)-4'-氯(或溴)-2',4'-二氢-2,5'-二甲基-2'-苯基螺[1,3'-3'获得了H-吡唑] -3-酮6b和7b(或6c和7c)。用2-氨基-N-甲基-N-(1-苯基-3-甲基-1H-吡唑-5-基)苯甲酰胺处理重氮卤化物(氯化物和溴化物)1b,c得到相同的差向异构体合适的经典桑德梅尔催化剂。螺环化合物的形成基于连续的Pschorr和Sandmeyer反应。确定了差向异构体2和10的X射线晶体结构,证实了给定的配方。 [参考:21]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号